research Telogen Effluvium Post-COVID: An Integrative Review
COVID-19 can cause temporary hair loss.
Search
for
Sort by
Research
390-420 / 689 results 
research Alopecia and COVID-19: Possible Etiopathogenetic Variants and Therapeutic Approach
COVID-19 may cause hair loss, often after recovery, with androgenetic alopecia being the most common type.
research Acute Telogen Effluvium: A Post-Covid-19 Sequela
COVID-19 infection may cause hair loss.
research Pathogenetic Features of the Influence of a Past Coronavirus Infection in Women with Polycystic Ovarian Syndrome
Women with PCOS are more vulnerable to severe COVID-19 and related health issues.
research Impact of the COVID-19 Pandemic on Tertiary Care University Dermatology Outpatient Clinic and Dermatology Procedures
The COVID-19 pandemic led to fewer patient visits, more visits by older adults, an increase in cutaneous T-cell lymphoma cases, and a rise in noncosmetic procedures at a dermatology clinic.
research A Hair Loss Pandemic: 19 Cases of COVID-19 Induced Telogen Effluvium
COVID-19 can cause hair loss in both severe and mild cases, often affecting women.
research A Systematic Review and Quality Evaluation of Studies on Long-Term Sequelae of COVID-19
COVID-19 can cause long-term lung, skin, and mental health problems, especially in women, people with other health issues, and those who had severe COVID-19.
research What We Already Know About the Post-Covid-19 Syndrome: A Narrative Review
Long-lasting symptoms like fatigue and breathlessness can persist after COVID-19, requiring ongoing medical follow-up.
research Dermatological Manifestations of Patients with COVID-19: A Cross-Sectional Study
COVID-19 can cause skin problems.
research Free Testosterone Levels in Patients with COVID-19 and Its Association with Disease Severity
People with lower levels of free testosterone tend to have worse COVID-19 outcomes.
research Reporting Cases of Telogen Effluvium as a Sequelae of COVID-19 Infection
COVID-19 can cause temporary hair loss, known as Telogen Effluvium, within two months of infection.
research Reply to Early Onset Effluvium Secondary to COVID-19 and Body-Hair Effluvium
COVID-19 can cause different types of hair loss, which may last up to 100 days, and treatments are still being explored.
research Hair Loss Associated with COVID-19: Problems and Solutions
COVID-19 can cause temporary hair loss due to stress and inflammation.
research COVID-19 Can Exacerbate Pattern Hair Loss and Trigger Telogen Effluvium: The Role of Proteoglycan Replacement Therapy with Nourkrin in Clinical Treatment of COVID-19 Associated Hair Loss
COVID-19 may worsen hair loss, and Nourkrin® could be a safe treatment option, but more research is needed.
research Whole Plant Adiantum Capillus-Veneris Linn Extract as an Anti-COVID-19 Therapy
Maidenhair fern extract might help treat COVID-19 symptoms, but more research is needed.
research Dermatological Manifestations of COVID-19 and Its Therapies: A Review
COVID-19 can cause skin symptoms that might help spot the virus early, and treatments for it can also affect the skin.
research Reply to Comment on: The Gabrin Sign
Men with male pattern baldness may be more at risk for severe COVID-19, and anti-androgen treatments could offer protection.
research Adiantum Capillus-Veneris Linn (Maidenhair Fern) Extract-Based Drug as a Symptomatic Treatment for COVID-19
Maidenhair fern extract may help treat COVID-19 symptoms.
research Humoral Immune Response to COVID-19 Vaccination in Psoriasis Patients on Biologic Therapy Is Impaired Compared to Healthy Controls
Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
research Cutaneous Manifestations and Considerations in COVID-19 Pandemic: A Systematic Review
COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.
research Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019
Some people who recover from COVID-19 continue to have symptoms like fatigue and cough for over 120 days, and some experience hair loss about 59 days after getting sick.
research An Update on Antiviral Treatment of COVID-19
As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.
research Acute Generalized Exanthematous Pustulosis Induced by Hydroxychloroquine Prescribed for COVID-19
A patient developed a severe skin reaction and died after taking hydroxychloroquine for COVID-19.
research The Use of Mesenchymal Stromal Cells in the Treatment of Coronavirus Disease 2019
Mesenchymal stromal cells may help treat severe COVID-19, but more research is needed to confirm their effectiveness.
research Public Interest in Dermatologic Symptoms, Conditions, Treatments, and Procedures During the COVID-19 Pandemic: Insights from Google Trends
Public interest in skin issues changed during COVID-19, with more focus on dry skin, hair problems, and hand eczema.
research Are Nutraceuticals Effective in Covid-19 and Post-Covid Prevention and Treatment?
Some nutraceuticals may help in COVID-19 prevention and treatment, but more research is needed.
research Roles of Steroid Receptors in the Lung and COVID-19
Sex hormones may influence COVID-19 severity, with males at higher risk, and certain hormone therapies could potentially treat the virus.
research Transitional Changes in Fatigue-Related Symptoms Due to Long COVID: A Single-Center Retrospective Observational Study in Japan
Patients with long COVID after Omicron had fewer hospitalizations and milder symptoms but more fatigue, insomnia, and cough compared to those with Delta.
research Alopecia Areata Occurring After COVID-19 Vaccination: A Single-Center, Cross-Sectional Study
Some people developed alopecia areata after COVID-19 vaccination, but it's not caused by the vaccine and most improved with treatment.
research Proxalutamide Reduces Hospitalization Rate in Mild-to-Moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Trial
Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.